The Fact.MR new report on the market survey of Melanoma Cancer Diagnostics gives estimations of the Size of Melanoma Cancer Diagnostics Market and the overall Melanoma Cancer Diagnostics Market share of key regional segments During Forecast Period.
The latest market research report analyzes Melanoma Cancer Diagnostics Market demand by Different segments. Providing business leaders with insights On Melanoma Cancer Diagnostics And how they can increase their market share.
The Demand of Melanoma Cancer Diagnostics Market study includes the current market scenario on the global platform and also Sales of Melanoma Cancer Diagnostics Market development during the forecast period.
Melanoma Cancer Diagnostics Market: segmentation
- Fluorescent In Situ Hybridization (FISH) Tests
- Comparative Genomic Hybridization (CGH) Tests
- Immunohistochemical (IHC) Tests
- Pathology Laboratories
- Cancer Research Centres
- North America
- Latin America
- CIS & Russia
- Middle East & Africa
Fluorescent In Situ Hybridization (FISH) Emerging Highly Preferred Test Type
High sensitivity, specificity and speed at which assays can be performed is resulting in significant use of Fluorescent In Situ Hybridization (FISH) test in both research and diagnosis of skin cancer and solid tumors. Fact.MR expects FISH Test to witness steady growth, exceeding US$ 300 million in 2018.
FISH is offering identification of genetic changes that are too small to be visible under microscope. Moreover, FISH test is not required to be performed on the cells actively dividing making it faster than other types of test. With an emphasis on early detection of skin cancer, FISH is becoming a vital tool to detect cancer. FISH is also witnessing significant adoption in detecting melanoma cancer diagnosis compared to Comparative Genomic Hybridization (CGH) Tests, owing to the technical limitations in CGH.